pharma
Novartis’ gene therapy Luxturna becomes first approved European therapy for vision loss subtype
November 23, 2018Medical Communications, Sales and Marketing EU, Europe, Luxturna, Novartis, pharma, vision loss
Novartis has revealed that its one-time gene therapy Luxturna (voretigene neparvovec) has been awarded approval by the European Commission to …
Cancer Drugs Fund to offer MSD’s Keytruda for lung cancer
November 22, 2018Sales and Marketing CDF, Cancer, Cancer Drugs Fund, NHS, NICE, UK, keytruda, pharma
MSD’s Keytruda (pembrolizumab) will now be made available via the Cancer Drugs Fund for patients in England, as NICE announces …
FDA approves first ever therapy for ultra rare primary haemophagocytic lymphohistiocytosis
November 21, 2018Research and Development, Sales and Marketing FDA, Novimmune, pharma, sobi
The partnership of Sobi and Novimmune has revealed that their interferon gamma (IFNγ) blocking antibody Gamifant (emapalumab-lzsg) has received approval …
Mylan’s Morgantown plant receives FDA warning letter
November 21, 2018Research and Development Mylan, pharma
Generic drugmaker Mylan has received a warning letter from the FDA over concerns surrounding the firm’s manufacturing plant in West …
MHRA Chief to step down in 2019
November 21, 2018Medical Communications, Research and Development MHRA, UK, brexit, pharma
The Medicines and Healthcare products Regulatory Agency (MHRA), the regulator responsible for the efficacy and safety of medicines in the …
First-ever all-oral drug for sleeping sickness recommended for approval by EMA committee
November 20, 2018Manufacturing and Production, Sales and Marketing CHMP, EMA, Europe, Sanofi, fexinidazole, pharma, sleeping sickness
Sanofi’s fexinidazole, the first all-oral therapy for the treatment of human African trypanosomiasis (HAT), or sleeping sickness, has secured a …
Opioid dependency therapy price hiked 600% since 2014, Senate investigators find
November 20, 2018Manufacturing and Production, Sales and Marketing Evzio, Kaleo, Senate, US, naloxone, opioid crisis, opioid epidemic, opioids, pharma
Senate investigators have found that Virginia-based drugmaker Kaleo hiked the price of its opioid dependency therapy Evzio (naloxone) by as …
Merck KGaA and Pfizer’s Bavencio falls short in ovarian cancer
November 20, 2018Manufacturing and Production, Research and Development Bavencio, Cancer, Merck MGaA, Pfizer, ovarian cancer, pharma
Merck KGaA and Pfizer’s Bavencio (avelumab) has missed its primary endpoints in the treatment of platinum-resistant or -refractory ovarian cancer, …
Pfizer to resume price hiking in 2019; 41 drugs set to increase
November 20, 2018Manufacturing and Production, Sales and Marketing Pfizer, Trump, pharma, price hikes, price hiking, pricing
American pharma firm Pfizer has revealed plans to increase the prices of 41 medicines, the equivalent of 10% of its …
Eli Lilly’s Emgality cleared for treatment of migraine in Europe
November 20, 2018Manufacturing and Production, Sales and Marketing EU, Eli Lilly, Emgality, Europe, migraine, pharma
Eli Lilly’s Emgality (galcanezumab) has secured approval from the European Commission for the prophylaxis of migraine in adult patients who …
Novartis’ Promacta cleared by FDA for first-line use in severe aplastic anaemia
November 19, 2018Sales and Marketing FDA, Novartis, Promacta, Revolade, US, aplastic anaemia, pharma
Novartis has secured expanded approval from the FDA for Promacta (eltrombopag), allowing it to now be used in combination with …
Roche withdraws Tecentriq combo application in first-line renal cell carcinoma
November 19, 2018Sales and Marketing Cancer, Roche, avastin, pharma, renal cell carcinoma, tecentriq
The EMA has revealed that Roche has chosen to withdraw its marketing application for immunotherapy Tecentriq (atezolizumab) in combination with …
MSD’s Keytruda to treat melanoma in England on the Cancer Drugs Fund
November 19, 2018Sales and Marketing England, MSD, NHS, UK, keytruda, melanoma, pharma
MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) will now be made available to patients in England via the Cancer Drugs Fund, it …
AstraZeneca’s Imfinzi immunotherapy combo fails to show benefit in lung cancer
November 16, 2018Medical Communications, Research and Development AstraZeneca, Cancer, Imfinzi, lung cancer, pharma
AstraZeneca has revealed that its immunotherapy combo of Imfinzi (durvalumab) and tremelimumab failed to meet its primary endpoint in a …
Kymriah to be made available in UK for paediatric leukaemia patients via Cancer Drugs Fund
November 15, 2018Sales and Marketing CAR-T, Cancer, Cancer Drugs Fund, Kymriah, NHS, NICE, leukaemia, pharma
NICE has announced its recommendation that Novartis’ CAR-T cell therapy Kymriah (tisagenlecleucel) be made available in the treatment of relapsed …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
